Computer simulations of bioequivalence trials: Selection of design and analyte in BCS drugs with first-pass hepatic metabolism: Linear kinetics (I)

European Journal of Pharmaceutical Sciences

Volumn 36, Issue 1, 2009, Pages 137-146

  Fernández Teruel, Carlos ^a   Nalda Molina, Ricardo ^a   González Alvarez, Isabel ^b   Navarro Fontestad, Carmen ^a   García Arieta, Alfredo ^c   Casabó, Vicente G ^a   Bermejo, Marival ^b  

^a UNIVERSITY OF VALENCIA   (Spain)

^b Facultad de Farmacia   (Spain)

^c Pharmacokinetics Service   (Spain)

Author keywords

BCS; Bioequivalence; First pass metabolism; Linear; Single dose; Steady state

Indexed keywords

AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; COMPUTER SIMULATION; DRUG CLEARANCE; DRUG METABOLISM; DRUG PENETRATION; DRUG SOLUBILITY; FIRST PASS EFFECT; LIVER METABOLISM; MAXIMUM PLASMA CONCENTRATION; MONTE CARLO METHOD; PRIORITY JOURNAL; SINGLE DRUG DOSE; STATISTICAL ANALYSIS; STEADY STATE;

ALGORITHMS; AREA UNDER CURVE; COMPUTER SIMULATION; DATA INTERPRETATION, STATISTICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LIVER; NONLINEAR DYNAMICS; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; THERAPEUTIC EQUIVALENCY; TISSUE DISTRIBUTION;

EID: 58149129024     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2008.10.014     Document Type: Article

References (25)

1. Amidon G.L., Lennernas H., Shah V.P., and Crison J.R. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 12 (1995) 413-420
2. Blume H.H., and Midha K.K. Bio-International 92, conference on bioavailability, bioequivalence, and pharmacokinetic studies. J. Pharm. Sci. 82 (1993) 1186-1189
3. Blume H.H., and Schug B.S. The biopharmaceutics classification system (BCS): class III drugs - better candidates for BA/BE waiver?. Eur J. Pharm. Sci. 9 (1999) 117-121
4. Chen M.L., and Jackson A.J. The role of metabolites in bioequivalency assessment. I. Linear pharmacokinetics without first-pass effect. Pharm. Res. 8 (1991) 25-32
5. Chen M.L., and Jackson A.J. The role of metabolites in bioequivalency assessment. II. Drugs with linear pharmacokinetics and first-pass effect. Pharm. Res. 12 (1995) 700-708
6. el-Tahtawy A.A., Jackson A.J., and Ludden T.M. Comparison of single and multiple dose pharmacokinetics using clinical bioequivalence data and Monte Carlo simulations. Pharm. Res. 11 (1994) 1330-1336
7. max. Pharm. Res. 12 (1995) 1634-1641
8. max. Pharm. Res. 15 (1998) 98-104
9. EMEA, 2001. CPMP/EWP/QWP/1401/98 Note For Guidance on Investigation of Bioavailability and Bioequivalence.
10. EMEA, 2006. CHMP/EWP/40326/2006 Efficacy Working Party. Questions and Answers on the Bioavailability and Bioequivalence Guideline.
11. Ezan E., Ardouin T., Delhotal Landes B., Flouvat B., Hanslik T., Legeai J.M., and Grognet J.M. Bioequivalence study of alpha-dihydroergocryptine: utility of metabolite evaluation. Int. J. Clin. Pharmacol. Ther. 34 (1996) 32-37
12. FDA, 2000. Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System.
13. FDA, 2003. Guidance for Industry Bioavailability and Bioequivalence Studies for Orally Administered Drug Products - General Considerations.
14. Jackson A.J. Prediction of steady-state bioequivalence relationships using single dose data I-linear kinetics. Biopharm. Drug Disposition 8 (1987) 483-496
15. Jackson A.J. Prediction of steady state bioequivalence relationships using single dose data II-nonlinear kinetics. Biopharm. Drug Disposition 10 (1989) 489-503
16. Jackson A.J. The role of metabolites in bioequivalency assessment. III. Highly variable drugs with linear kinetics and first-pass effect. Pharm. Res. 17 (2000) 1432-1436
17. Kortejarvi H., Urtti A., and Yliperttula M. Pharmacokinetic simulation of biowaiver criteria: the effects of gastric emptying, dissolution, absorption and elimination rates. Eur J. Pharm. Sci. 30 (2007) 155-166
18. Mahmood I. Assessment of metabolites in bioequivalence studies: should bioequivalence criteria be applied on the sum of parent compound and metabolite?. Int. J. Clin. Pharmacol. Ther. 36 (1998) 540-544
19. Polli J.E., Rekhi G.S., Augsburger L.L., and Shah V.P. Methods to compare dissolution profiles and a rationale for wide dissolution specifications for metoprolol tartrate tablets. J. Pharm. Sci. 86 (1997) 690-700
20. Rosenbaum S.E. Effects of variability in hepatic clearance on the bioequivalence parameters of a drug and its metabolite: simulations using a pharmacostatistical model. Pharm Acta Helv. 73 (1998) 135-144
21. Rosenbaum S.E., and Lam J. Bioequivalence Parameters of Parent Drug and Its First-Pass Metabolite: Comparative Sensitivity to Sources of Pharmacokinetic Variability. Drug Dev. Ind. Pharm. 23 (1997) 337-344
22. Tucker G.T., Rostami-Hodjegan A., and Jackson P.R. Bioequivalence-a measure of therapeutic equivalence?. In: Midha K.K., and Blume H.H. (Eds). Bio-International: Bioavailability, Bioequivalence and Pharmacokinetics. (1993), Medpharm Scientific Publishers, Stuttgart 35-43
23. Tucker G.T., Rostami-Hodjegan A., and Jackson P.R. Metabolite measurement in bioequivalence studies: Theoretical considerations. In: Midha K.K., and Blume H.H. (Eds). Bio-International: Bioavailability, Bioequivalence and Pharmacokinetics. (1993), Medpharm Scientific Publishers, Stuttgart 163-170
24. Wu C.Y., and Benet L.Z. Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm. Res. 22 (2005) 11-23
25. Zha J., and Endrenyi L. Variation of the peak concentration following single and repeated drug administrations in investigations of bioavailability and bioequivalence. J. Biopharm. Stat. 7 (1997) 191-204